flow trial semaglutide kidney outcomes results 2024 LANDMARK ALERT 🚨 REPRIEVE Trial results: Pitavastatin provides over 35% reduction in MACE in patients with HIV! FLOW trial for semaglutide kidney

we provide continuous support, monitoring your progress and making adjustments as needed

Supports natural GLP-1 activity pathways*

Research findings are summarized in a new Quick Take video

In meeting rooms and newspapers across Massachusetts, insurers revealed that GLP-1 drugs made up nearly 20% of their total pharmacy spending in 2024, calling them the single largest driver of its rising costs

One medical perspective highlights that reported hair loss may be indirectly related to stressors such as rapid weight reduction, nutritional gaps, or a temporary condition known as telogen effluvium rather than a direct pharmacologic effect

Wegovy is prescribed for adults with a body mass index (BMI) of 30 kg/m or greater or for those with a BMI of 27 kg/m or greater who have at least one weight-related comorbidity (such as type 2 diabetes, high blood pressure, or high cholesterol)